Craig L. Slingluff, Jr MD

GetPhoto.ashx?photo=cls8h_217

Primary Appointment

Professor, Surgery

Education

  • BA, Echols Scholar, University of Virginia
  • MD, Medicine, University of Virginia School of Medicine, Charlottesville, VA
  • Fellowship, Surgical Oncology, Duke University School of Medicine, Durham, NC
  • Resident, Surgery, Duke University School of Medicine, Durham, NC

Research Interests

Melanoma immunobiology, Cancer Vaccines, Clinical Trials, Tumor microenvironment

Research Description

Contributions to Science
1. Identification of Class I MHC-restricted peptides recognized by cancer-reactive T-cells and testing of peptide vaccines incorporating them.
2. Development and optimization of a multipeptide vaccine inducing CD4+ helper T cell responses to melanoma.
3. T-cell retention and dysfunction at the vaccine-site microenvironment (VSME), after vaccinating with short peptides in incomplete Freund√Ęs adjuvant (IFA), may be mediated by retention integrins.
4. Defining patterns of immune cell infiltration into the melanoma tumor microenvironment (TME) and potential barriers to immune infiltrates, and their associations with clinical outcome.
5. Identifying and characterizing the significance of tertiary lymphoid structures (TLS) in melanoma.
Links to all published work: At MyBibliography:
https://www-ncbi-nlm-nih-gov.proxy01.its.virginia.edu/myncbi/craig.slingluff.1/bibliography/public/
Current research projects:
A. Cancer vaccines using peptides combined with agonistic antibodies to costimulatory molecules CD27 and CD40, or with inhibitors of mutated BRAF.
B. Antibodies to melanoma peptides induce by vaccination and associated with improved survival.
C. Understanding the immunologic effects of vaccine adjuvants in the vaccine site microenvironment in the skin and in vaccine-draining lymph nodes
D. VITILs: Vaccine-induce tumor-infiltrating lymphocytes: using high-throughput TCR sequencing to identify T cells induced by vaccination that infiltrate melanoma metastases.
E. Focused ultrasound mediated immune therapy of cancer
F. Precision Lymph Node Dissection (PLND): Evaluating a low morbidity approach to managing patients with clinically detected melanoma metastasis isolated to one regional node. This includes genomic and gene expression studies to identify patients with just one pathologic node.
G. Barrier molecule genes and the Epidermal Differentiation Complex (EDC) genes and their roles in melanoma progression and immunobiology.
H. Retention integrins: roles of integrins CD49a, CD49b, CD103 in T cell retention in the tumor microenvironment
I. Tertiary lymphoid structures in primary desmoplastic melanoma and in melanoma metastases: understanding T cell priming in TLS and implications for clinical outcome.

Personal Statement

I have 30 years of experience as an independent investigator as a translational immunologist, surgical oncologist, and clinical trialist. My research in cancer immunology and immunotherapy includes laboratory studies and clinical trials that are broadly relevant to development and testing of therapeutic vaccines. After initial studies defining human melanoma antigens recognized by T cells, my focus has primarily been on developing cancer vaccines and combination immunotherapy. I have designed and run more than 25 investigator-initiated clinical trials testing cancer vaccines, targeted therapies, intraoperative imaging, and surgical technology. My primary clinical target is melanoma, though our team has also tested novel immunotherapy for other cancers. Our studies have identified promising clinical and immunologic outcomes with peptide vaccines, and have enhanced understanding of optimal vaccine adjuvants and the effects of those adjuvants on the vaccine site microenvironment. The impact of cancer vaccines and other immune therapies depends on the ability of T cells to infiltrate melanoma metastases and to function there. Thus, we also have identified critical roles of chemokines and integrins for T cell homing and retention as well as genes associated with lack of immune infiltration. Recent work has also characterized the heterogeneity of tertiary lymphoid structures in melanomas and their clinical implications. We are pursuing clinical trials of immune therapies that may modulate the tumor microenvironment to support antigen-directed tumor control. I have mentored over 30 postdoctoral fellows, 36 students, and many junior faculty.

Training

  • Cancer Research Training in Molecular Biology
  • Interdisciplinary Training Program in Immunology

Selected Publications

2022

Marsh, K. M., Lattimore, C. M., Cramer, C. L., Jr, S. C. L., & Dengel, L. T. (2022). Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma. JOURNAL OF SURGICAL ONCOLOGY, 126(7), 1272-1278. doi:10.1002/jso.27022

Shannon, A. B., III, S. R. J., Carr, M. J., Sun, J., Landa, K., Baecher, K., . . . Miura, J. T. (2022). ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. ANNALS OF SURGICAL ONCOLOGY, 29(11), 7045-7046. doi:10.1245/s10434-022-12293-7

Shannon, A. B., III, S. R. J., Carr, M. J., Sun, J., Landa, K., Baecher, K., . . . Miura, J. T. (2022). An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. ANNALS OF SURGICAL ONCOLOGY, 29(11), 7033-7044. doi:10.1245/s10434-022-12201-z

Lattimore, C. M., Meneveau, M. O., Marsh, K. M., Shada, A. L., Slingluff, C. L., & Dengel, L. T. (2022). A Novel Fascial Flap Technique After Inguinal Complete Lymph Node Dissection for Melanoma. JOURNAL OF SURGICAL RESEARCH, 278, 356-363. doi:10.1016/j.jss.2022.04.039

Vavolizza, R. D., Petroni, G. R., Mauldin, I. S., Chianese-Bullock, K. A., Olson, W. C., Smith, K. T., . . . Jr, S. C. L. (2022). Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naive and PD-1 antibody-experienced patients with melanoma (MEL64). JOURNAL FOR IMMUNOTHERAPY OF CANCER, 10(9). doi:10.1136/jitc-2022-005424

Crystal, J. S., Thompson, J. F., Hyngstrom, J., Caraco, C., Zager, J. S., Jahkola, T., . . . Lymphadenectomy, M. S. (2022). Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma A Randomized Clinical Trial. JAMA SURGERY, 157(9), 835-842. doi:10.1001/jamasurg.2022.2055

Biermann, J., Melms, J. C., Amin, A. D., Wang, Y., Caprio, L. A., Karz, A., . . . Izar, B. (2022). Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. CELL, 185(14), 2591-+. doi:10.1016/j.cell.2022.06.007

Tieniber, A. D., Shannon, A. B., Carr, M. J., Sun, J., Landa, K., Baecher, K. M., . . . Miura, J. T. (2022). Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysis.. Journal of the American Academy of Dermatology, S0190-9622(22)00813-1. doi:10.1016/j.jaad.2022.05.019

Jaiswal, A., Verma, A., Dannenfelser, R., Melssen, M., Tirosh, I., Izar, B., . . . Anandasabapathy, N. (2022). An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. CANCER CELL, 40(5), 524-+. doi:10.1016/j.ccell.2022.04.005

Meneveau, M. O., Kumar, P., Lynch, K. T., Patel, S. P., & Slingluff, C. L. (2022). The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 10(3). doi:10.1136/jitc-2021-003533

Sharib, J., Jr, S. C. L., & Beasley, G. M. (2022). Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. JOURNAL OF SURGICAL ONCOLOGY, 125(1), 28-33. doi:10.1002/jso.26717

Lynch, K. T., Squeo, G. C., Kane, W. J., Meneveau, M. O., Petroni, G., Olson, W. C., . . . Friel, C. M. (2022). A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, 150(1), 164-173. doi:10.1002/ijc.33793

2021

Mauldin, I. S., Jo, J., Wages, N. A., Yogendran, L. V., Mahmutovic, A., Young, S. J., . . . Fadul, C. E. (2021). Proliferating CD8(+) T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. CELLS, 10(12). doi:10.3390/cells10123378

Lulu, A. M., Cummings, K. L., Jeffery, E. D., Myers, P. T., Underwood, D., Lacy, R. M., . . . Engelhard, V. H. (2021). Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. CANCER IMMUNOLOGY RESEARCH, 9(11), 1327-1341. doi:10.1158/2326-6066.CIR-21-0111

III, S. R. J., Carr, M. J., Sinnamon, A. J., Shannon, A. B., Sun, J., Landa, K., . . . Miura, J. T. (2021). Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. ANNALS OF SURGICAL ONCOLOGY, 28(12), 6995-7003. doi:10.1245/s10434-021-10031-z

Kunk, P. R., Dougherty, S. C., Lynch, K., Whitehair, R., Meneveau, M., Obeid, J. M., . . . Rahma, O. E. (2021). Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location. JOURNAL OF IMMUNOTHERAPY, 44(7), 254-263. doi:10.1097/CJI.0000000000000378

Kwak, M., Erdag, G., Leick, K. M., Bekiranov, S., Engelhard, V. H., & Slingluff, C. L. (2021). Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163(+) myeloid cell infiltrates. JOURNAL OF TRANSLATIONAL MEDICINE, 19(1). doi:10.1186/s12967-021-03044-5

Pinczewski, J., Obeng, R. C., Jr, S. C. L., & Engelhard, V. H. (2021). Phospho-beta-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. PATHOLOGY RESEARCH AND PRACTICE, 224. doi:10.1016/j.prp.2021.153527

Melssen, M. M., Pollack, K. E., Meneveau, M. O., Smolkin, M. E., Pinczewski, J., Koeppel, A. F., . . . Jr, S. C. L. (2021). Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. CANCER IMMUNOLOGY IMMUNOTHERAPY, 70(8), 2151-2164. doi:10.1007/s00262-020-02844-w

Rodriguez, A. B., Peske, J. D., Woods, A. N., Leick, K. M., Mauldin, I. S., Meneveau, M. O., . . . Engelhard, V. H. (2021). Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. CELL REPORTS, 36(3). doi:10.1016/j.celrep.2021.109422

Banerjee, A., Li, D., Guo, Y., Mahgoub, B., Paragas, L., Slobin, J., . . . Krupnick, A. S. (2021). Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy. JOURNAL OF IMMUNOLOGY, 207(1), 333-343. doi:10.4049/jimmunol.2000926

Lynch, K. T., Kane, W. J., II, F. M. A., Desai, R. P., Showalter, S. L., Jr, S. C. L., . . . Hedrick, T. L. (2021). Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer. JOURNAL OF SURGICAL ONCOLOGY, 124(1), 16-24. doi:10.1002/jso.26478

Lynch, K. T., Young, S. J., Meneveau, M. O., Wages, N. A., Engelhard, V. H., Jr, S. C. L., & Mauldin, I. S. (2021). Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(6). doi:10.1136/jitc-2020-002273

Lynch, K. T., Gradecki, S. E., Kwak, M., Meneveau, M. O., Wages, N. A., Gru, A. A., & Jr, S. C. L. (2021). IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 45(6), 787-795. doi:10.1097/PAS.0000000000001622

Meneveau, M. O., Petroni, G. R., Salerno, E. P., Lynch, K. T., Smolkin, M., Woodson, E., . . . Slingluff, C. L. (2021). Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(5). doi:10.1136/jitc-2020-002214

Melssen, M. M., Lindsay, R. S., Stasiak, K., Rodriguez, A. B., Briegel, A. M., Cyranowski, S., . . . Engelhard, V. H. (2021). Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8(+) T Cells. CANCER IMMUNOLOGY RESEARCH, 9(5), 583-597. doi:10.1158/2326-6066.CIR-20-0427

Hsueh, E. C., DeBloom, J. R., Lee, J. H., Sussman, J. J., Covington, K. R., Caruso, H. G., . . . McMasters, K. M. (2021). Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. JCO PRECISION ONCOLOGY, 5, 589-601. doi:10.1200/PO.20.00119

Gradecki, S. E., Jr, S. C. L., & Gru, A. A. (2021). PRAME expression in 155 cases of metastatic melanoma. JOURNAL OF CUTANEOUS PATHOLOGY, 48(4), 479-485. doi:10.1111/cup.13876

Patel, S. P., Petroni, G. R., Roszik, J., Olson, W. C., Wages, N. A., Chianese-Bullock, K. A., . . . Slingluff, C. L. (2021). Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(8). doi:10.1136/jitc-2021-003220

Meneveau, M. O., Sahli, Z. T., Lynch, K. T., Mauldin, I. S., & Jr, S. C. L. (2021). Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes. MELANOMA, 2265, 515-528. doi:10.1007/978-1-0716-1205-7_36

Mauldin, I. S., Mahmutovic, A., Young, S. J., & Jr, S. C. L. (2021). Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures. MELANOMA, 2265, 573-587. doi:10.1007/978-1-0716-1205-7_40

Jr, S. C. L., Zarour, H. M., Tawbi, H. A. -H., Kirkwood, J. M., Postow, M. A., Friedlander, P., . . . Wolchok, J. D. (2021). A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. ONCOIMMUNOLOGY, 10(1). doi:10.1080/2162402X.2021.1898105

Jr, S. C. L., Petroni, G. R., Chianese-Bullock, K. A., Wages, N. A., Olson, W. C., Smith, K. T., . . . Hall, E. H. (2021). Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). JOURNAL FOR IMMUNOTHERAPY OF CANCER, 9(1). doi:10.1136/jitc-2020-000934

2020

Kogler, A. K., Polemi, A. M., Nair, S., Majewski, S., Dengel, L. T., Jr, S. C. L., . . . Williams, M. B. (2020). Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients. EJNMMI RESEARCH, 10(1). doi:10.1186/s13550-020-00729-8

Kwak, M., Erdag, G., & Jr, S. C. L. (2020). Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. SCIENTIFIC REPORTS, 10(1). doi:10.1038/s41598-020-74996-9

Grasso, C. S., Tsoi, J., Onyshchenko, M., Abril-Rodriguez, G., Ross-Macdonald, P., Wind-Rotolo, M., . . . Ribas, A. (2020). Conserved Interferon-gamma Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. CANCER CELL, 38(4), 500-+. doi:10.1016/j.ccell.2020.08.005

Arora, P., Talamo, L., Dillon, P., Gentzler, R. D., Millard, T., Salerno, M., . . . Gaughan, E. M. (2020). Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. CARDIO-ONCOLOGY, 6(1). doi:10.1186/s40959-020-00076-6

Wages, N. A., & Jr, S. C. L. (2020). Flexible Phase I-II Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. STATISTICS IN BIOSCIENCES, 12(2), 104-123. doi:10.1007/s12561-019-09245-3

Jr, S. C. L. (2020). Building on the Promise of Cancer Vaccines for Solid Tumors. CLINICAL CANCER RESEARCH, 26(3), 529-531. doi:10.1158/1078-0432.CCR-19-3206

Gastman, B., Agarwal, P. K., Berger, A., Boland, G., Broderick, S., Butterfield, L. H., . . . Kaufman, H. L. (2020). Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(2). doi:10.1136/jitc-2020-001583

Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese-Bullock, K. A., . . . Jr, S. C. L. (2020). MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(1). doi:10.1136/jitc-2019-000262

Pollack, K. E., Meneveau, M. O., Melssen, M. M., Lynch, K. T., Koeppel, A. F., Young, S. J., . . . Jr, S. C. L. (2020). Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(1). doi:10.1136/jitc-2020-000544

Dillon, P. M., Brenin, C. M., & Jr, S. C. L. (2020). Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data. BREAST CANCER-TARGETS AND THERAPY, 12, 69-75. doi:10.2147/BCTT.S224758

Wages, N. A., Jr, S. C. L., Bullock, T. N., & Petroni, G. R. (2020). Tailoring early-phase clinical trial design to address multiple research objectives. CANCER IMMUNOLOGY IMMUNOTHERAPY, 69(1), 95-102. doi:10.1007/s00262-019-02442-5

2019

Leick, K. M., Obeid, J. M., Bekiranov, S., & Jr, S. C. L. (2019). Systems analysis of barrier molecule and ARNT-related gene expression regulation in melanoma. ONCOIMMUNOLOGY, 8(12). doi:10.1080/2162402X.2019.1665978

Kwak, M., Song, Y., Gimotty, P. A., Farrow, N. E., Tieniber, A. D., Davick, J. G., . . . Karakousis, G. C. (2019). Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis (vol 26, pg 3962, 2019). ANNALS OF SURGICAL ONCOLOGY, 26, S893. doi:10.1245/s10434-019-08046-8

Kwak, M., Song, Y., Gimotty, P. A., Farrow, N. E., Tieniber, A. D., Davick, J. G., . . . Karakousis, G. C. (2019). Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. ANNALS OF SURGICAL ONCOLOGY, 26(12), 3962-3971. doi:10.1245/s10434-019-07694-0

Leick, K. M., Rodriguez, A. B., Melssen, M. M., Benamar, M., Lindsay, R. S., Eki, R., . . . Jr, S. C. L. (2019). The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis. ANNALS OF SURGERY, 270(4), 712-722. doi:10.1097/SLA.0000000000003522

Kwak, M., Mehaffey, J. H., Hawkins, R. B., Hedrick, T. L., Jr, S. C. L., Schirmer, B., . . . Friel, C. M. (2019). Bariatric surgery is independently associated with a decrease in the development of colorectal lesions. SURGERY, 166(3), 322-326. doi:10.1016/j.surg.2019.03.013

Kwak, M., Leick, K. M., Melssen, M. M., & Jr, S. C. L. (2019). Vaccine Strategy in Melanoma. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 28(3), 337-+. doi:10.1016/j.soc.2019.02.003

Melssen, M. M., Petroni, G. R., Chianese-Bullock, K. A., Wages, N. A., Grosh, W. W., Varhegyi, N., . . . Jr, S. C. L. (2019). A multipeptide vaccine plus toll-like receptor agonists LPS or polylCLC in combination with incomplete Freund's adjuvant in melanoma patients. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 7. doi:10.1186/s40425-019-0625-x

Kwak, M., Farrow, N. E., Salama, A. K. S., Mosca, P. J., Hanks, B. A., Slingluff, C. L., & Beasley, G. M. (2019). Updates in adjuvant systemic therapy for melanoma. JOURNAL OF SURGICAL ONCOLOGY, 119(2), 222-231. doi:10.1002/jso.25298

Gemta, L. F., Siska, P. J., Nelson, M. E., Gao, X., Liu, X., Locasale, J. W., . . . Bullock, T. N. J. (2019). Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8(+) T cells. SCIENCE IMMUNOLOGY, 4(31). doi:10.1126/sciimmunol.aap9520

2018

Goudreau, B. J., Hassinger, T. E., Hedrick, T. L., Jr, S. C. L., Schroen, A. T., & Dengel, L. T. (2018). Academic or community practice? What is driving decision-making and career choices. SURGERY, 164(3), 571-576. doi:10.1016/j.surg.2018.05.003

Stowman, A. M., Hickman, A. W., Mauldin, I. S., Mahmutovic, A., Gru, A. A., & Jr, S. C. L. (2018). Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. MELANOMA RESEARCH, 28(3), 237-245. doi:10.1097/CMR.0000000000000439

Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., . . . Kaufman, H. L. (2018). An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 6. doi:10.1186/s40425-018-0362-6

Michaels, A. D., Newhook, T. E., Adair, S. J., Morioka, S., Gaudreau, B. J., Nagdas, S., . . . Bauer, T. W. (2018). CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. CLINICAL CANCER RESEARCH, 24(6), 1415-1425. doi:10.1158/1078-0432.CCR-17-2283

Knapp, K. A., Pires, E. S., Adair, S. J., Mandal, A., Mills, A. M., Olson, W. C., . . . Herr, J. C. (2018). Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.. Oncotarget, 9(10), 8972-8984. doi:10.18632/oncotarget.23944

Obeid, J. M., Kunk, P. R., Zaydfudim, V. M., Bullock, T. N., Jr, S. C. L., & Rahma, O. E. (2018). Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. CANCER IMMUNOLOGY IMMUNOTHERAPY, 67(2), 161-174. doi:10.1007/s00262-017-2082-z

Engelhard, V. H., Rodriguez, A. B., Mauldin, I. S., Woods, A. N., Peske, J. D., & Jr, S. C. L. (2018). Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. JOURNAL OF IMMUNOLOGY, 200(2), 432-442. doi:10.4049/jimmunol.1701269

Melssen, M. M., Olson, W., Wages, N. A., Capaldo, B. J., Mauldin, I. S., Mahmutovic, A., . . . Jr, S. C. L. (2018). Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. ONCOIMMUNOLOGY, 7(10). doi:10.1080/2162402X.2018.1490855

2017

Dillon, P. M., Petroni, G. R., Smolkin, M. E., Brenin, D. R., Chianese-Bullock, K. A., Smith, K. T., . . . Jr, S. C. L. (2017). A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5. doi:10.1186/s40425-017-0295-5

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., . . . Chan, T. A. (2017). Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. CELL, 171(4), 934-+. doi:10.1016/j.cell.2017.09.028

Hsueh, E. C., DeBloom, J. R., Lee, J., Sussman, J. J., Covington, K. R., Middlebrook, B., . . . McMasters, K. M. (2017). Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test (vol 10, 152, 2017). JOURNAL OF HEMATOLOGY & ONCOLOGY, 10. doi:10.1186/s13045-017-0524-x

Beasley, G. M., Hu, Y., Youngwirth, L., Scheri, R. P., Salama, A. K., Rossfeld, K., . . . Terando, A. M. (2017). Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. ANNALS OF SURGICAL ONCOLOGY, 24(9), 2728-2733. doi:10.1245/s10434-017-5883-6

Shukla, G. S., Olson, W. C., Pero, S. C., Sun, Y. -J., Carman, C. L., Jr, S. C. L., & Krag, D. N. (2017). Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. JOURNAL OF TRANSLATIONAL MEDICINE, 15. doi:10.1186/s12967-017-1283-8

Hsueh, E. C., DeBloom, J. R., Lee, J., Sussman, J. J., Covington, K. R., Middlebrook, B., . . . McMasters, K. M. (2017). Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. JOURNAL OF HEMATOLOGY & ONCOLOGY, 10. doi:10.1186/s13045-017-0520-1

Meissen, M., & Jr, S. C. L. (2017). Vaccines targeting helper T cells for cancer immunotherapy. CURRENT OPINION IN IMMUNOLOGY, 47, 85-92. doi:10.1016/j.coi.2017.07.004

Stowman, A. M., Hickman, A. W., Gru, A. A., & Jr, S. C. L. (2017). Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry. MELANOMA RESEARCH, 27(4), 369-376. doi:10.1097/CMR.0000000000000361

Hu, Y., Edwards, B. L., Hu, K., Brooks, K. D., & Jr, S. C. L. (2017). Surgery investigators funded through the National Institutes of Health: A rebirth. SURGERY, 161(6), 1482-1488. doi:10.1016/j.surg.2016.12.004

Obeid, J. M., Hu, Y., Erdag, G., Leick, K. M., & Jr, S. C. L. (2017). The heterogeneity of tumor-infiltrating CD8(+) T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?. MELANOMA RESEARCH, 27(3), 211-217. doi:10.1097/CMR.0000000000000330

Wages, N. A., Jr, S. C. L., & Petroni, G. R. (2017). Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies. ANNALS OF ONCOLOGY, 28(4), 696-701. doi:10.1093/annonc/mdw681

Obeid, J. M., Wages, N. A., Hu, Y., Deacon, D. H., & Jr, S. C. L. (2017). Heterogeneity of CD8(+) tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. CANCER IMMUNOLOGY IMMUNOTHERAPY, 66(1), 33-43. doi:10.1007/s00262-016-1908-4

2016

Reuss, J. E., Kunk, P. R., Stowman, A. M., Gru, A. A., Jr, S. C. L., & Gaughan, E. M. (2016). Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 4. doi:10.1186/s40425-016-0199-9

Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., . . . Jr, S. C. L. (2016). Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(10), 1189-1199. doi:10.1007/s00262-016-1881-y

Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Olson, W. C., Deacon, D. H., . . . Jr, S. C. L. (2016). Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(10), 1201-1212. doi:10.1007/s00262-016-1880-z

Benamar, M., Guessous, F., Du, K., Corbett, P., Obeid, J., Gioeli, D., . . . Abbas, T. (2016). Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBIOMEDICINE, 10, 85-100. doi:10.1016/j.ebiom.2016.06.023

Weber, J. S., Gibney, G., Sullivan, R. J., Sosman, J. A., Jr, S. C. L., Lawrence, D. P., . . . Hodi, F. S. (2016). Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. LANCET ONCOLOGY, 17(7), 943-955. doi:10.1016/S1470-2045(16)30126-7

Gentzler, R., Hall, R., Kunk, P. R., Gaughan, E., Dillon, P., Jr, S. C. L., & Rahma, O. E. (2016). Beyond melanoma: inhibiting the PD-1/PDL-1 pathway in solid tumors. IMMUNOTHERAPY, 8(5), 583-600. doi:10.2217/imt-2015-0029

Kunk, P. R., Bauer, T. W., Slingluff, C. L., & Rahma, O. E. (2016). From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 4. doi:10.1186/s40425-016-0119-z

Jacquelot, N., Enot, D. P., Flament, C., Vimond, N., Blattner, C., Pitt, J. M., . . . Zitvogel, L. (2016). Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. JOURNAL OF CLINICAL INVESTIGATION, 126(3), 921-937. doi:10.1172/JCI80071

Hu, Y., Melmer, P. D., & Slingluff, C. L. (2016). Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye. ANNALS OF SURGERY, 263(3), 588-592. doi:10.1097/SLA.0000000000001187

Salerno, E. P., Bedognetti, D., Mauldin, I. S., Deacon, D. H., Shea, S. M., Pinczewski, J., . . . Jr, S. C. L. (2016). Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. ONCOIMMUNOLOGY, 5(12). doi:10.1080/2162402X.2016.1240857

Obeid, J. M., Erdag, G., Smolkin, M. E., Deacon, D. H., Patterson, J. W., Chen, L., . . . Slingluff, C. L. (2016). PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. ONCOIMMUNOLOGY, 5(11). doi:10.1080/2162402X.2016.1235107

Ladoire, S., Senovilla, L., Enot, D., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., . . . Kroemer, G. (2016). Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. ONCOIMMUNOLOGY, 5(6). doi:10.1080/2162402X.2016.1160193

Jr, S. C. L., Petroni, G. R., Olson, W. C., Smolkin, M. E., Chianese-Bullock, K. A., Mauldin, I. S., . . . Grosh, W. W. (2016). A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(1), 25-36. doi:10.1007/s00262-015-1770-9

2015

Ramirez, A. G., Wages, N. A., Hu, Y., Smolkin, M. E., & Jr, S. C. L. (2015). Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience. CANCER IMMUNOLOGY IMMUNOTHERAPY, 64(12), 1531-1539. doi:10.1007/s00262-015-1758-5

Dengel, L. T., Petroni, G. R., Judge, J., Chen, D., Acton, S. T., Schroen, A. T., & Jr, S. C. L. (2015). Total body photography for skin cancer screening. INTERNATIONAL JOURNAL OF DERMATOLOGY, 54(11), 1250-1254. doi:10.1111/ijd.12593

Capaldo, B. J., Roller, D., Axelrod, M. J., Koeppel, A. F., Petricoin, E. F., Jr, S. C. L., . . . Bekiranov, S. (2015). Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. PLOS ONE, 10(9). doi:10.1371/journal.pone.0138210

Hu, Y., Kim, H., Blackwell, C. M., & Jr, S. C. L. (2015). Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. ANNALS OF SURGERY, 262(3), 456-464. doi:10.1097/SLA.0000000000001419

Reed, C. M., Cresce, N. D., Mauldin, I. S., Jr, S. C. L., & Olson, W. C. (2015). Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. CLINICAL CANCER RESEARCH, 21(17), 3879-3887. doi:10.1158/1078-0432.CCR-15-0233

Mauldin, I. S., Wang, E., Deacon, D. H., Olson, W. C., Bao, Y., & Jr, S. C. L. (2015). TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. INTERNATIONAL JOURNAL OF CANCER, 137(6), 1386-1396. doi:10.1002/ijc.29515

Obeid, J., Hu, Y., & Jr, S. C. L. (2015). Vaccines, Adjuvants, and Dendritic Cell Activators-Current Status and Future Challenges. SEMINARS IN ONCOLOGY, 42(4), 549-561. doi:10.1053/j.seminoncol.2015.05.006

Hu, Y., Edwards, B. L., Brooks, K. D., Newhook, T. E., & Jr, S. C. L. (2015). Recent trends in National Institutes of Health funding for surgery: 2003 to 2013. AMERICAN JOURNAL OF SURGERY, 209(6), 1083-1089. doi:10.1016/j.amjsurg.2015.01.015

Hu, Y., Shah, P., Stukenborg, G. J., & Jr, S. C. L. (2015). Utility of Sentinel Lymph Node Biopsy for Solitary Dermal Melanomas. JOURNAL OF SURGICAL ONCOLOGY, 111(7), 800-807. doi:10.1002/jso.23890

Wages, N. A., Conaway, M. R., Jr, S. C. L., Williams, M. E., Portell, C. A., Hwu, P., & Petroni, G. R. (2015). Recent developments in the implementation of novel designs for early-phase combination studies. ANNALS OF ONCOLOGY, 26(5), 1036-1037. doi:10.1093/annonc/mdv075

Wages, N. A., Jr, S. C. L., & Petroni, G. R. (2015). A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. CONTEMPORARY CLINICAL TRIALS, 41, 172-179. doi:10.1016/j.cct.2015.01.016

2014

Zarling, A. L., Obeng, R. C., Desch, A. N., Pinczewski, J., Cummings, K. L., Deacon, D. H., . . . Engelhard, V. H. (2014). MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.. Cancer research, 74(23), 6784-6795. doi:10.1158/0008-5472.can-14-0043

Zarling, A. L., Obeng, R. C., Desch, A. N., Pinczewski, J., Cummings, K. L., Deacon, D. H., . . . Engelhard, V. H. (2014). MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. CANCER RESEARCH, 74(23), 6784-6795. doi:10.1158/0008-5472.CAN-14-0043

Hu, Y., Smolkin, M. E., White, E. J., Petroni, G. R., Neese, P. Y., & Jr, S. C. L. (2014). Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma. ANNALS OF SURGICAL ONCOLOGY, 21(12), 3978-3984. doi:10.1245/s10434-014-3794-3

Schroen, A. T., & Jr, S. C. L. (2014). Discussions About Clinical Trials Among Patients With Newly Diagnosed Lung and Colorectal Cancer. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(10). doi:10.1093/jnci/dju265

Hu, Y., Petroni, G. R., Olson, W. C., Czarkowski, A., Smolkin, M. E., Grosh, W. W., . . . Jr, S. C. L. (2014). Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine (vol 63, pg 779, 2014). CANCER IMMUNOLOGY IMMUNOTHERAPY, 63(10), 1113. doi:10.1007/s00262-014-1601-4

Strickler, A. G., Schaefer, J. T., Jr, S. C. L., & Wick, M. R. (2014). Immunolabeling for p16, WT1, and Fli-1 in the Assignment of Growth Phase for Cutaneous Melanomas. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 36(9), 718-722. Retrieved from https://www.webofscience.com/

Hu, Y., Petroni, G. R., Olson, W. C., Czarkowski, A., Smolkin, M. E., Grosh, W. W., . . . Jr, S. C. L. (2014). Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. CANCER IMMUNOLOGY IMMUNOTHERAPY, 63(8), 779-786. doi:10.1007/s00262-014-1551-x

Liu, Q., Tomei, S., Ascierto, M. L., De Giorgi, V., Bedognetti, D., Dai, C., . . . Marincola, F. M. (2014). Melanoma NOS1 expression promotes dysfunctional IFN signaling. JOURNAL OF CLINICAL INVESTIGATION, 124(5), 2147-2159. doi:10.1172/JCI69611

Salerno, E. P., Olson, W. C., McSkimming, C., Shea, S., & Jr, S. C. L. (2014). T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. INTERNATIONAL JOURNAL OF CANCER, 134(3), 563-574. doi:10.1002/ijc.28391

Judge, J. M., Stukenborg, G. J., Johnston, W. F., Guilford, W. H., Jr, S. C. L., & Hallowell, P. T. (2014). Design, Development, and Evaluation of a Novel Retraction Device for Gallbladder Extraction During Laparoscopic Cholecystectomy. JOURNAL OF GASTROINTESTINAL SURGERY, 18(2), 334-339. doi:10.1007/s11605-013-2292-4

Kaufman, H. L., Ruby, C. E., Hughes, T., & Jr, S. C. L. (2014). Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2. doi:10.1186/2051-1426-2-11

Dillon, P. M., Olson, W. C., Czarkowski, A., Petroni, G. R., Smolkin, M., Grosh, W. W., . . . Jr, S. C. L. (2014). A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2. doi:10.1186/2051-1426-2-23

2013

Clancy-Thompson, E., King, L. K., Nunnley, L. D., Mullins, I. M., Jr, S. C. L., & Mullins, D. W. (2013). Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen-Specific CD8 T Cells. CANCER IMMUNOLOGY RESEARCH, 1(5), 332-339. doi:10.1158/2326-6066.CIR-13-0084

Jr, S. C. L., Lee, S., Zhao, F., Chianese-Bullock, K. A., Olson, W. C., Butterfield, L. H., . . . Kirkwood, J. M. (2013). A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). CLINICAL CANCER RESEARCH, 19(15), 4228-4238. doi:10.1158/1078-0432.CCR-13-0002

Judge, J. M., II, B. L. B., Smith, K. T., Deacon, D. H., Patterson, J. W., Grosh, W. W., . . . Jr, S. C. L. (2013). A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(8), 1327-1334. doi:10.1007/s00262-013-1433-7

Salerno, E. P., Shea, S. M., Olson, W. C., Petroni, G. R., Smolkin, M. E., McSkimming, C., . . . Jr, S. C. L. (2013). Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(7), 1149-1159. doi:10.1007/s00262-013-1435-5

Jr, S. C. L., Petroni, G. R., Molhoek, K. R., Brautigan, D. L., Chianese-Bullock, K. A., Shada, A. L., . . . Weber, M. J. (2013). Clinical Activity and Safety of Combination Therapy with Temsirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). CLINICAL CANCER RESEARCH, 19(13), 3611-3620. doi:10.1158/1078-0432.CCR-12-3919

Shada, A. L., Dengel, L. T., Petroni, G. R., Smolkin, M. E., Acton, S., & Jr, S. C. L. (2013). Infrared thermography of cutaneous melanoma metastases. JOURNAL OF SURGICAL RESEARCH, 182(1), E9-E14. doi:10.1016/j.jss.2012.09.022

Judge, J. M., Tillou, J. D., Jr, S. C. L., Kern, J. A., Kron, I. L., & Weiss, G. R. (2013). Surgical Management of the Patient with Metastatic Melanoma to the Heart. JOURNAL OF CARDIAC SURGERY, 28(2), 124-128. doi:10.1111/jocs.12054

Judge, J. M., Chianese-Bullock, K. A., Schroen, A. T., & Jr, S. C. L. (2013). Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. CLINICAL TRIALS, 10(1), 143-150. doi:10.1177/1740774512464438

2012

Schroen, A. T., Thielen, M. J., Turrentine, F. E., Kron, I. L., & Jr, S. C. L. (2012). Research incentive program for clinical surgical faculty associated with increases in research productivity. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 144(5), 1003-1009. doi:10.1016/j.jtcvs.2012.07.033

McClain, S. E., Shada, A. L., Barry, M., Patterson, J. W., & Jr, S. C. L. (2012). Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. MELANOMA RESEARCH, 22(4), 302-309. doi:10.1097/CMR.0b013e328353e673

Wagenseller, A. G., Shada, A. L., D'Auria, K., Murphy, C. F., Sun, D., Molhoek, K. R., . . . Slingluff, C. L. (2012). MicroRNAs induced in melanoma treated with combination targeted therapy of temsirolimus and bevacizumab. JOURNAL OF CLINICAL ONCOLOGY, 30(15). Retrieved from https://www.webofscience.com/

McClain, S. E., Mayo, K. B., Shada, A. L., Smolkin, M. E., Patterson, J. W., & Slingluff, C. L. (2012). Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences. INTERNATIONAL JOURNAL OF DERMATOLOGY, 51(4), 420-426. doi:10.1111/j.1365-4632.2011.05066.x

Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., . . . Jr, S. C. L. (2012). Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. CANCER RESEARCH, 72(5), 1070-1080. doi:10.1158/0008-5472.CAN-11-3218

Shada, A. L., Walters, D. M., Tierney, S. N., & Jr, S. C. L. (2012). Surgical resection for bulky or recurrent axillary metastatic melanoma. JOURNAL OF SURGICAL ONCOLOGY, 105(1), 21-25. doi:10.1002/jso.22058

Harris, R. C., Chianese-Bullock, K. A., Petroni, G. R., Schaefer, J. T., II, B. L. B., Molhoek, K. R., . . . Jr, S. C. L. (2012). The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides. JOURNAL OF IMMUNOTHERAPY, 35(1), 78-88. doi:10.1097/CJI.0b013e31823731a4

Schroen, A. T., Petroni, G. R., Wang, H., Thielen, M. J., Gray, R., Benedetti, J., . . . Jr, S. C. L. (2012). Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from US Cooperative Oncology Groups. CLINICAL CANCER RESEARCH, 18(1), 256-262. doi:10.1158/1078-0432.CCR-11-1633

2011

Molhoek, K. R., Erdag, G., Rasamny, J., Murphy, C., Deacon, D., Patterson, J. W., . . . Brautigan, D. L. (2011). VEGFR-2 expression in human melanoma: revised assessment. INTERNATIONAL JOURNAL OF CANCER, 129(12), 2807-2815. doi:10.1002/ijc.25963

Weiss, G. R., Grosh, W. W., Chianese-Bullock, K. A., Zhao, Y., Liu, H., Jr, S. C. L., . . . Wang, E. (2011). Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma. CLINICAL CANCER RESEARCH, 17(23), 7440-7450. doi:10.1158/1078-0432.CCR-11-1650

Schroen, A. T., Petroni, G. R., Wang, H., Thielen, M. J., Sargent, D., Benedetti, J. K., . . . Djulbegovic, B. (2011). Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. CLINICAL TRIALS, 8(5), 591-600. doi:10.1177/1740774511419683

Molhoek, K. R., Shada, A. L., Smolkin, M., Chowbina, S., Papin, J., Brautigan, D. L., & Jr, S. C. L. (2011). Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. MELANOMA RESEARCH, 21(4), 274-284. doi:10.1097/CMR.0b013e328343a1d6

Jr, S. C. L., Petroni, G. R., Chianese-Bullock, K. A., Smolkin, M. E., Ross, M. I., Haas, N. B., . . . Grosh, W. W. (2011). Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine. JOURNAL OF CLINICAL ONCOLOGY, 29(21), 2924-2932. doi:10.1200/JCO.2010.33.8053

Butterfield, L. H., Palucka, A. K., Britten, C. M., Dhodapkar, M. V., Hakansson, L., Janetzki, S., . . . Disis, M. L. (2011). Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. CLINICAL CANCER RESEARCH, 17(10), 3064-3076. doi:10.1158/1078-0432.CCR-10-2234

Shada, A. L., & Jr, S. C. L. (2011). Regional Control and Morbidity After Superficial Groin Dissection in Melanoma. ANNALS OF SURGICAL ONCOLOGY, 18(5), 1453-1459. doi:10.1245/s10434-010-1450-0

Dengel, L. T., More, M. J., Judy, P. G., Petroni, G. R., Smolkin, M. E., Rehm, P. K., . . . Jr, S. C. L. (2011). Intraoperative Imaging Guidance for Sentinel Node Biopsy in Melanoma Using a Mobile Gamma Camera. ANNALS OF SURGERY, 253(4), 774-778. doi:10.1097/SLA.0b013e3181f9b709

Olson, W. C., Smolkin, M. E., Farris, E. M., Fink, R. J., Czarkowski, A. R., Fink, J. H., . . . Jr, S. C. L. (2011). Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. JOURNAL OF TRANSLATIONAL MEDICINE, 9. doi:10.1186/1479-5876-9-26

Mohr, M. R., Erdag, G., Shada, A. L., Williams, M. E., Jr, S. C. L., & Patterson, J. W. (2011). Two Patients With Hailey-Hailey Disease, Multiple Primary Melanomas, and Other Cancers. ARCHIVES OF DERMATOLOGY, 147(2), 211-215. doi:10.1001/archdermatol.2010.445

Jr, S. C. L. (2011). The Present and Future of Peptide Vaccines for Cancer Single or Multiple, Long or Short, Alone or in Combination?. CANCER JOURNAL, 17(5), 343-350. doi:10.1097/PPO.0b013e318233e5b2

2010

Mikesh, L. M., Kumar, M., Erdag, G., Hogan, K. T., Molhoek, K. R., Mayo, M. W., & Jr, S. C. L. (2010). Evaluation of molecular markers of mesenchymal phenotype in melanoma. MELANOMA RESEARCH, 20(6), 485-495. doi:10.1097/CMR.0b013e32833fafb4

Hennessy, S. A., Dengel, L. T., Hranjec, T., & Jr, S. C. L. (2010). A Triangular Intermuscular Space Sentinel Node in Melanoma: Association With Axillary Lymphatic Drainage. ANNALS OF SURGICAL ONCOLOGY, 17(9), 2465-2470. doi:10.1245/s10434-010-1018-z

Schaefer, J. T., Patterson, J. W., Deacon, D. H., Smolkin, M. E., Petroni, G. R., Jackson, E. M., & Jr, S. C. L. (2010). Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. JOURNAL OF TRANSLATIONAL MEDICINE, 8. doi:10.1186/1479-5876-8-79

Schroen, A. T., Petroni, G. R., Wang, H., Gray, R., Wang, X. F., Cronin, W., . . . Jr, S. C. L. (2010). Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. CLINICAL TRIALS, 7(4), 312-321. doi:10.1177/1740774510374973

Shada, A. L., Molhoek, K. R., & Jr, S. C. L. (2010). Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma. CANCER JOURNAL, 16(4), 360-366. doi:10.1097/PPO.0b013e3181eb3393

Dengel, L. T., Norrod, A. G., Gregory, B. L., Clancy-Thompson, E., Burdick, M. D., Strieter, R. M., . . . Mullins, D. W. (2010). Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma. JOURNAL OF IMMUNOTHERAPY, 33(9), 965-974. doi:10.1097/CJI.0b013e3181fb045d

Turza, K., Dengel, L. T., Harris, R. C., Patterson, J. W., White, K., Grosh, W. W., & Jr, S. C. L. (2010). Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. JOURNAL OF CUTANEOUS PATHOLOGY, 37(1), 94-98. doi:10.1111/j.1600-0560.2009.01290.x

Jr, S. C. L., Petroni, G. R., Smolkin, M. E., Chianese-Bullock, K. A., Smith, K., Murphy, C., . . . Kirkwood, J. M. (2010). Immunogenicity for CD8(+) and CD4(+) T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines. JOURNAL OF IMMUNOTHERAPY, 33(6), 630-638. doi:10.1097/CJI.0b013e3181e311ac